Indianapolis-based Eli Lilly and Co. has made a breakthrough in treating the Coronavirus, one that will have huge global implications. The U.S. FDA has granted Emergency Use Authorization for a COVID-19 antibody therapy developed by Lilly. The treatment, known as bamlanivimab, will soon be available to treat recently diagnosed, high-risk patients. For more on the treatment and timeline is Chief Financial Officer Josh Smiley.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}